MX2020013302A - Métodos y composiciones para prevenir o tratar calcificación de tejido. - Google Patents
Métodos y composiciones para prevenir o tratar calcificación de tejido.Info
- Publication number
- MX2020013302A MX2020013302A MX2020013302A MX2020013302A MX2020013302A MX 2020013302 A MX2020013302 A MX 2020013302A MX 2020013302 A MX2020013302 A MX 2020013302A MX 2020013302 A MX2020013302 A MX 2020013302A MX 2020013302 A MX2020013302 A MX 2020013302A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- prevent
- methods
- tissue calcification
- progression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682796P | 2018-06-08 | 2018-06-08 | |
| PCT/US2019/036138 WO2019237053A1 (en) | 2018-06-08 | 2019-06-07 | Methods and compositions for preventing or treating tissue calcification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013302A true MX2020013302A (es) | 2021-05-12 |
Family
ID=68765387
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013302A MX2020013302A (es) | 2018-06-08 | 2019-06-07 | Métodos y composiciones para prevenir o tratar calcificación de tejido. |
| MX2024013515A MX2024013515A (es) | 2018-06-08 | 2020-12-07 | Metodos y composiciones para prevenir o tratar calcificacion de tejido |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013515A MX2024013515A (es) | 2018-06-08 | 2020-12-07 | Metodos y composiciones para prevenir o tratar calcificacion de tejido |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US10688064B2 (enExample) |
| EP (1) | EP3801477A4 (enExample) |
| JP (2) | JP2021527128A (enExample) |
| KR (1) | KR20210018423A (enExample) |
| CN (1) | CN113038940A (enExample) |
| AU (1) | AU2019282420B2 (enExample) |
| CA (1) | CA3102977A1 (enExample) |
| IL (1) | IL279245B2 (enExample) |
| MX (2) | MX2020013302A (enExample) |
| SG (1) | SG11202012070YA (enExample) |
| WO (1) | WO2019237053A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019237054A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
| IL279245B2 (en) | 2018-06-08 | 2024-03-01 | Epizon Pharma Inc | Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification |
| WO2020055678A1 (en) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
| MX2021010977A (es) * | 2019-03-12 | 2021-12-10 | Nattopharma As | Uso de vitamina k en combinacion con anticoagulantes. |
| KR20240045216A (ko) * | 2021-07-05 | 2024-04-05 | 위니베르시테이트 마스트리흐트 | 칼슘 결정 침착 질환의 치료 수단 및 방법 |
| WO2023129413A1 (en) * | 2021-12-31 | 2023-07-06 | Ingredient Fusion, Llc | Molecular complexing method, formulation and manufacturing for enhanced nutrient delivery |
| WO2024071848A1 (ko) * | 2022-09-27 | 2024-04-04 | 경북대학교 산학협력단 | 혈관석회화 치료제 스크리닝 방법 |
| WO2025075468A1 (ko) * | 2023-10-06 | 2025-04-10 | 주식회사 레드엔비아 | 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176778A1 (en) | 2001-08-03 | 2005-08-11 | Vitak Bv | Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification |
| WO2005030190A1 (en) * | 2003-09-26 | 2005-04-07 | Natural Asa | Natural menaquinone 7 compositions |
| SI1728507T1 (sl) | 2005-06-03 | 2011-07-29 | Nattopharma Asa | Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil |
| EP2046312B1 (en) * | 2006-07-14 | 2020-02-19 | Kaydence Pharma AS | Pharmaceutical and nutraceutical products comprising vitamin k2 |
| GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
| WO2012059942A2 (en) | 2010-11-01 | 2012-05-10 | Viridis Biopharma Pvt. Ltd | Dynamic balancing of autonomic nervous system through vitamin mk-7 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| ES2869202T3 (es) | 2012-06-18 | 2021-10-25 | Fresenius Kabi Deutschland Gmbh | Sistema de cánula para vía para la punción de vías centrales de acceso subcutáneo |
| WO2014191466A1 (en) | 2013-05-28 | 2014-12-04 | Nattopharma Asa | Menaquinone supplementation and vascular health |
| GB201314245D0 (en) | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
| WO2016131993A2 (en) * | 2015-02-20 | 2016-08-25 | Vitak B.V. | Vitamin k and capillary function |
| MX2017011934A (es) | 2015-03-20 | 2018-02-09 | Gnosis Spa | Formas solidas de menaquinoles. |
| IT201700085412A1 (it) | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
| US10368858B1 (en) | 2018-01-25 | 2019-08-06 | Ring Orthopedics, Inc. | Suture passer |
| WO2019237054A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
| IL279245B2 (en) | 2018-06-08 | 2024-03-01 | Epizon Pharma Inc | Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification |
-
2019
- 2019-06-07 IL IL279245A patent/IL279245B2/en unknown
- 2019-06-07 US US16/435,241 patent/US10688064B2/en active Active
- 2019-06-07 EP EP19814212.7A patent/EP3801477A4/en active Pending
- 2019-06-07 KR KR1020217000120A patent/KR20210018423A/ko not_active Ceased
- 2019-06-07 SG SG11202012070YA patent/SG11202012070YA/en unknown
- 2019-06-07 CA CA3102977A patent/CA3102977A1/en active Pending
- 2019-06-07 MX MX2020013302A patent/MX2020013302A/es unknown
- 2019-06-07 CN CN201980052695.9A patent/CN113038940A/zh active Pending
- 2019-06-07 JP JP2021518056A patent/JP2021527128A/ja active Pending
- 2019-06-07 WO PCT/US2019/036138 patent/WO2019237053A1/en not_active Ceased
- 2019-06-07 AU AU2019282420A patent/AU2019282420B2/en active Active
-
2020
- 2020-03-12 US US16/817,347 patent/US10874623B2/en active Active
- 2020-03-12 US US16/817,374 patent/US10744102B2/en active Active
- 2020-03-12 US US16/817,363 patent/US10744101B2/en active Active
- 2020-11-20 US US17/100,256 patent/US11033515B2/en active Active
- 2020-12-07 MX MX2024013515A patent/MX2024013515A/es unknown
-
2021
- 2021-05-11 US US17/317,488 patent/US11723882B2/en active Active
-
2023
- 2023-06-29 US US18/215,989 patent/US12377060B2/en active Active
-
2024
- 2024-03-19 JP JP2024043503A patent/JP7847880B2/ja active Active
-
2025
- 2025-06-12 US US19/236,367 patent/US20250302772A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240009144A1 (en) | 2024-01-11 |
| AU2019282420B2 (en) | 2025-03-20 |
| IL279245B1 (en) | 2023-11-01 |
| AU2019282420A1 (en) | 2021-01-07 |
| US20200206159A1 (en) | 2020-07-02 |
| US20210093584A1 (en) | 2021-04-01 |
| MX2024013515A (es) | 2024-12-06 |
| US11723882B2 (en) | 2023-08-15 |
| US20250302772A1 (en) | 2025-10-02 |
| WO2019237053A1 (en) | 2019-12-12 |
| IL279245B2 (en) | 2024-03-01 |
| CN113038940A (zh) | 2021-06-25 |
| US20210378986A1 (en) | 2021-12-09 |
| US11033515B2 (en) | 2021-06-15 |
| US20190374484A1 (en) | 2019-12-12 |
| JP2021527128A (ja) | 2021-10-11 |
| US12377060B2 (en) | 2025-08-05 |
| US20200222337A1 (en) | 2020-07-16 |
| JP2024073612A (ja) | 2024-05-29 |
| EP3801477A1 (en) | 2021-04-14 |
| IL279245A (en) | 2021-01-31 |
| US10744101B2 (en) | 2020-08-18 |
| EP3801477A4 (en) | 2022-02-23 |
| JP7847880B2 (ja) | 2026-04-20 |
| SG11202012070YA (en) | 2021-01-28 |
| KR20210018423A (ko) | 2021-02-17 |
| US10874623B2 (en) | 2020-12-29 |
| CA3102977A1 (en) | 2019-12-12 |
| US10744102B2 (en) | 2020-08-18 |
| US20200206158A1 (en) | 2020-07-02 |
| US10688064B2 (en) | 2020-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013302A (es) | Métodos y composiciones para prevenir o tratar calcificación de tejido. | |
| MX2024010211A (es) | Metodos y composiciones para prevenir o tratar calcifilaxis. | |
| PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| Disease et al. | KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| BR112018075288A2 (pt) | métodos para diagnóstico de infecções bacterianas e virais | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| MX381599B (es) | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| BR112015024537A8 (pt) | uso de um ou mais (i) ciclofosfamida, (ii) metformina e (iii) pelo menos um outro agente no tratamento de câncer, combinação, ciclofosfamida, metformina ou um agente | |
| BR112015023542A8 (pt) | uso de uma quantidade terapeuticamente eficaz de uma composição compreendendo adamts13 isolado | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| BR112017022394A2 (pt) | uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade | |
| MX2020009002A (es) | Fosfatasa alcalina recombinante para usarse en el tratamiento de lesion renal aguda asociada con sepsis. | |
| BR112018073355A2 (pt) | gordura e seus usos médicos | |
| MX2015010677A (es) | Composicion para tratar hemorroides. | |
| BR112018016651A2 (pt) | composições e métodos para tratamento de doença e distúrbios de sinusite | |
| MX2021010977A (es) | Uso de vitamina k en combinacion con anticoagulantes. | |
| Thet | Extension of calciphylaxis, bilateral skin necrosis and bilateral cerebral infarct: case report | |
| Ezer et al. | C110 MULTIDISCIPLINARY DIAGNOSIS, STAGING, AND TREATMENT OF THORACIC CANCERS: Evaluating Treatments For Older Patients With A Second Primary Lung Cancer | |
| TAO et al. | A clinical study of Mahuang-Fuzi-Xixin decoction and Wuling powder combined with routine western medicine therapy for chronic renal disease stage 3 |